Rising Incidence of Bone Metastasis in Solid Tumors Market Drive Innovation in Therapeutics
Bone metastasis commonly occurs in patients with advanced cancers like breast, lung, and prostate cancers. When cancer cells from a primary tumor spread to the bones, it causes severe bone pain, fractures, spinal cord compression, and hypercalcemia. Currently, there are limited treatment options for bone metastasis and palliative care involving analgesics, radiation therapy and bone-modifying agents are commonly used. However, the need for effective and long-lasting therapeutics is driving significant research and development in this market.
The bone metastasis in solid tumors market is estimated to be valued at USD 3.8 billion in 2024 and is expected to reach USD 6.73 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.
Key Takeaways
Key players operating in the bone metastasis in solid tumors market are Novartis, Merck & Co., Eli Lilly and Company, Amgen, Radius Health Inc.
Rising incidence of cancers with high risk of bone metastasis like breast and prostate cancer is a major factor fueling Bone Metastasis in Solid Tumors Market growth. According to Globocan 2020, over 2.3 million new cases of breast cancer and 1.4 million new cases of prostate cancer were reported worldwide.
Significant investments in developing novel drug delivery systems, bone targeting agents, radiopharmaceuticals and gene therapies are expected to bring innovative solutions and transform the treatment landscape over the coming years.
Market Trends
One of the major trends is the development of RANK ligand inhibitors for treatment of bone metastasis. Drugs like Xgeva by Amgen block RANK ligand activity and help reduce complications of bone disease.
Precision medicine using biomarkers is gaining attention with drugs being developed targeting specific mutations found in patients with higher risk of bone metastasis.
Market Opportunities
High unmet need in managing bone pain and complications presents significant scope for long-acting analgesics and bone-stabilizing agents.
Combination therapies using multiple mechanisms like blocking cancer cell growth and bone metastasis simultaneously holds promise. This can potentially achieve better clinical outcomes.
Impact of COVID-19 on Bone Metastasis in Solid Tumors Market Growth
The COVID-19 pandemic has significantly impacted the bone metastasis in solid tumors market. During the initial phase of the pandemic, cancer screening procedures and treatments were postponed to avoid virus transmission. This led to underdiagnosis and treatment delays for bone metastasis patients. However, treatments for advanced cases continued to avoid disease progression. With lifting of lockdowns, screening and routine treatments have resumed though at a slower pace due to safety protocols. Telehealth has emerged as an effective tool to provide consultations and address non-emergency cases.
The delays in screening and shift to telehealth is expected to continue affecting the market in the short-term. In the long run, rising cancer incidence post pandemic may see increased demand. Drug developers are accelerating clinical trials of novel agents through virtual approaches. Healthcare providers are implementing protocols to safely treat patients and minimize hospital visits. Governments are also supporting cancer care through policy reforms and funding. Adopting a hybrid model of care combining telehealth and hospital visits can help optimize resources and boost market recovery.
Geographical Concentration
In terms of geography, North America holds the major share of the bone metastasis in solid tumors market currently due to advanced healthcare systems and widespread medical insurance. Within the region, the United States contributes significantly owing to the large cancer patient pool and frequent adoption of new technologies. Europe is the second largest regional market aided by favorable reimbursements and government support for cancer research. Meanwhile, Asia Pacific is projected as the fastest growing region in the long run. This is attributed to growing medical tourism, increasing healthcare investments and expanding patient access in countries like China, India and South Korea.
Get More Insights On- Bone Metastasis in Solid Tumors Market
Get This Report in Japanese Language: 固形腫瘍における骨転移市場
Get This Report in Korean Language: 고형 종양 시장에서의 뼈 전이
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments
0 comment